Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Kristine Smedenfors"'
1
Akademický článek
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Autor: Malin Lindstedt, Peter Ellmark, Lennart Greiff, Karin Hägerbrand, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Anette Sundstedt, Adnan Deronic, Lill Ljung, Mattias Levin, Laura Varas, Anna Säll, Christina Sakellariou, Barnabas Nyesiga, David Gomez Jimenez, Mona Celander, Deniz Bölükbas, Fredrika Carlsson
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen pr
Externí odkaz: https://doaj.org/article/3ded16f9cf504c5983b33e362b58d5fd
Zobrazit plný text záznamu
2
Akademický článek
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Autor: Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in
Externí odkaz: https://doaj.org/article/ac146a36143540ed83d59ae4ac9773f4
Zobrazit plný text záznamu
4
Abstract 2444: The integrin alpha10beta1 antibody TARG10 reduces tumor growth and metastasis of triple negative breast cancer
Autor: Katarzyna Masoumi, Xiaoli Huang, Anna Mirkov, Kristine Smedenfors, Per Norlén, Evy Lundgren-Åkerlund
Publikováno v: Cancer Research. 82:2444-2444
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer that accounts for 10-15% of all breast cancer diagnoses. It is far more aggressive than other breast cancer types due to a higher degree of metastases and frequent relapses f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd0d4d96730fc44833f8a469df71a563
https://doi.org/10.1158/1538-7445.am2022-2444
Zobrazit plný text záznamu
5
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Autor: Sara Fritzell, Anne Månsson Kvarnhammar, Karin Enell Smith, Laura Von Schantz, Mia Thagesson, Doreen Werchau, Anna Rosén, Per Norlén, Karin Hägerbrand, Eva Nyblom, Peter Ellmark, Niina Veitonmäki, Christina Furebring, Kristine Smedenfors, Maria Johansson, Karin Barchan, Magnus Winnerstam, Ida Åberg, Anna Dahlman
Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many ind
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09cbba20b753513ce8ee3f014583fcfc
http://europepmc.org/articles/PMC6458634
Zobrazit plný text záznamu
6
Abstract 3623: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Autor: Per Norlén, Karin Hägerbrand, Anne Månsson-Kvarnhammar, Mia Thagesson, Kristine Smedenfors, Niina Veitonmäki, Anna Rosén, Peter Ellmark, Christina Furebring, Doreen Werchau, Maria C Johansson
Publikováno v: Cancer Research. 78:3623-3623
ATOR-1015 is a CTLA-4 x OX40 bispecific immune activating antibody developed for tumor-directed immunotherapy. ATOR-1015 binds both targets simultaneously, promoting cell-cell interactions expected to enhance the immuno-stimulating effect of the comp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::99798d935a49ff9eacda71fb81568f30
https://doi.org/10.1158/1538-7445.am2018-3623
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje